Key result
Reduced-intensity anticoagulation during ECMO mitigates bleeding risk with tailored monitoring.
Why the study?
Anticoagulation is among the most challenging aspects of ECMO because patients remain at risk of both bleeding and thrombosis, requiring synthesis of current evidence across anticoagulation agent, intensity, and monitoring.
This review highlights a shift toward reduced-intensity, individualized anticoagulation during contemporary ECMO, integrating choice of agent, intensity, and monitoring assays (such as anti-Xa) to balance bleeding and thrombotic risks.
Answers are grounded in this paper and cite their sources.
May inform individualized ECMO anticoagulation to balance risks; leaves open safe intensity thresholds for randomized trials.
Purpose of review Anticoagulation is among the most challenging aspects of extracorporeal membrane oxygenation (ECMO), during which patients remain at risk of both bleeding and thrombosis. This review synthesizes current evidence across the three interconnected domains of anticoagulation: agent, intensity, and monitoring. Recent findings Unfractionated heparin remains the first-line anticoagulant, although evidence supporting its superiority over alternative agents is limited. Direct thrombin inhibitors and, more recently, therapeutic low-molecular-weight heparin have emerged as alternatives. Anticoagulation intensity has historically lacked standardized definitions, while observational data linking higher activated partial thromboplastin time values to bleeding have contributed to a shift toward lower anticoagulation targets. Available assays provide complementary rather than interchangeable information, and no single test reliably reflects anticoagulant effect or predicts outcomes, although anti-Xa is emerging as the most informative single assay for unfractionated heparin. Summary Recent evidence supports reduced-intensity anticoagulation during contemporary ECMO, although the lower limit of safe anticoagulation remains undefined and no single agent, target, or assay is optimal for every patient. Anticoagulation should therefore be individualized by integrating agent, intensity, and monitoring according to patient characteristics, circuit performance, and the evolving balance between thrombosis and bleeding.
No takes yet. Share an insight, caveat, or question.
Giani et al. (2026) conducted a review in Extracorporeal membrane oxygenation (ECMO). Anticoagulation strategies (unfractionated heparin, direct thrombin inhibitors, therapeutic low-molecular-weight heparin) was evaluated on Bleeding and thrombosis during ECMO. Reduced-intensity anticoagulation during ECMO is supported by recent evidence to mitigate bleeding risk, requiring individualized selection of agent, intensity, and monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: